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but he cannot be investigated fully at every attendance. Any investigation in patients who are HIV positive are, by definition, kept to a minimum, particularly when they involve blood tests and endoscopy. It is therefore possible that a patient with Munchausen's can prolong his stay in hospital simply by informing the admitting doctor that he is HIV positive.
This patient was a significant hazard to staff. He was actively bleeding and took no precautions to contain the blood. On this admission he was known to be HIV positive but at all his medical consultations the following week, he failed to reveal this fact.
This case suggests the need for a register of patients who are HIV positive and have Munchausen's syndrome in order to protect hospital staff but the practicalities of absolute confidentiality, at present, prevent this. This case also emphasizes the importance of taking simple precautions to avoid contact with blood in all patients and not only those known to be at high risk. 
3D
-
IMedical Unit and 2Department of Haematology, Royal Infirmary, Glasgow G4 OSF Keywords: macroglobulinaemia; tremor A syndrome of hyperglobulinaemia and central nervous system affection was first described by Bing and Neel in 19361,but Waldenstrom's macroglobulinaemia, a condition of plasma and lymphoid cell proliferation resulting in IgM paraproteinaemia and diffuse plasmalymphoid infiltrates, was not described until 1944 2 • Central nervous system involvement (Bing-Neelsyndrome) has been found in about 25% of patients with macroglobulinaemia and usually presents as stroke, encephalopathy, myelopathy or peripheral neuropathy". We report on a patient who presented initially with an isolated extrapyramidal lesion and was subsequently found to have macroglobulinaemia.
Case report
A 56-year-old seaman presented with sudden onset bilateral tremor of the hands at rest which had remained unchanged for the last 10 weeks. He had a past history of alcohol abuse, but had abstained for the previous 6 years. Peripheral sensory neuropathy had been diagnosed 5 years previously.
On examination, there was a Parkinsonian tremor (frequency 6 hz), with typical 'pill-rolling' action at rest in both hands. Tone was normal, there was no bradykinesia and a negative glabellar tap. There was evidence of peripheral neuropathy with reduced cutaneous sensation over both feet, absent vibration sense and absent ankle reflexes in the lower limbs. Examination of the fundi was normal and no other abnormal physical signs were detected.
Initial investigations showed normochromic normocytic anaemia (Hb 10.6 g/dl) and a raised erythrocyte sedimentation rate (123 mm/hr). Thyroid function, serum caeruloplasmin, urinary copper excretion, CAT scan of head and electroencephalogram were all normal. Subsequent investigations showed reduced serum albumin (29 gil; normal 35-55 gil) and raised serum globulin (82 gil; normal 22-33 gil). The plasma IgM level was raised (76 gil; normal 0.3-4 gil), IgG and IgA levels were normal and there were no cryoglobulins. Marrow aspirate showed a dense infiltrate of small mature lymphocytes and plasma cells confirming the diagnosis ofWaldenstrom's macroglobulinaemia. Plasma viscosity was markedly raised at 4.006 cp (normal 1.45 cp, 37°C) and treatment was started with plasmapheresis (total of 16 litres exchanged), and chlorambucil 5 mg/day. While immunoglobulin and viscosity levels fell progressively (Figure 1) , the tremor remained unchanged, but no further signs of basal ganglia disease developed.
Discussion
The manifestations of Waldenstrom's macroglobulinaemia are due to two pathological processes: (i) IgM is a large, mainly intravascular, molecule which in excess increases red cell aggregation and plasma viscosity. This results in reduced blood flow causing vascular stasis, occlusion and ischaemia and a bleeding tendency due to interference with coagulation factors and platelet function; (ii) plasma and lymphoid cellular infiltrates may result in tumour masses resembling lymphoma or chronic lymphatic leukaemia. The mechanism of the neurological involvement is attributed to various pathologies. Strokes and encephalopathies have improved following plasmapheresis suggesting that reduced cerebral perfusion due to hyperviscosity was responsible", Some of the central effects may be due to haemorrhage or infarction and peripheral effects to ischaemia from red cell agglutination in the vasa nervorum" or deposition of IgM in myelin sheaths".
In the case reported here, the sudden onset and nature of the tremor suggests a small infarct or haemorrhage in the basal ganglia region, although no structural lesion was visualized and there were no other haemorrhagic manifestations. Failure of the tremor to improve despite treatment ofhyperviscosity also supports a more permanent lesion. Previously gross tremor of both hands in a patient with Waldenstrom's macroglobulinaemia has been described, but with no obvious Parkinsonian features", The cause of the peripheral neuropathy remains obscure; it is atypical of the Bing-Neel syndrome since it had been documented for at least 5 years before diagnosis of macroglobulinaemia, although a previous case has been reported where neuropathy was present four years before macroglobulinaemia was diagnosed". It remains possible that it was secondary to longstanding alcohol abuse.
This patient's presentation of macroglobulinaemia with a single manifestation of basal ganglia disease is rare. We would suggest that it is worthwhile checking serum proteins in any middle-aged or elderly patient with unusual central nervous system signs and/or peripheral neuropathy when other causes have been excluded.
The anxiogenic jungle of modern civilization produces many varied and persisting stresses that create anxiety in many people. Should we use anxiolytic drugs to help them survive when their coping mechanisms fail? Or should we use a non-drug approach? The meeting addressed itself to these problems and a number of distinguished speakers covered differing aspects of the subject.
The diverse uses ofbenzodiazepines(BDZs) in clinical practice were considered by Michael Trimble (National Hospital for Nervous Diseases) who emphasized that any equation of BDZs with anxiety is misleading since these drugs have myorelaxant, anticonvulsant, sedative and amnesic properties, all of which have been used for their clinical effects. For example, the 1,5 BDZ clobazam is a broad-spectrum anticonvulsant used as adjunctive therapy in epilepsy; whilst spasticity and dystonic syndromes variably respond to the muscle relaxant properties ofthe BDZs. They have been used as amnesic agents prior to surgery and also have potential use in affective disorders such as, for example, mania. BDZswith short elimination half-lives can be recommended as hypnotics and also in severe anxiety unresponsive to behavioural treatments and in trauma-induced acute anxiety.
Dr Peter Tyrer (St Charles Hospital, London) emphasized that BDZ use is still over-shadowed by the risks of dependence and this dwarfs all other problems posed by these drugs. Recent research has been directed towards better identification of the factors predisposing to dependence: dosage, duration of treatment, type of BDZ and personality status of the consumers. Against the dangers of dependence must be balanced the relative merits of long-term use in: panic disorder, recurring neurotic symptomatology and intermittent alcohol abuse. Other problems are the type and extent of cognitive and sensorimotor impairment, lack of efficacyafter repeated dosage and illegal use of BDZs.
Many of the problems with the BDZs are related to the pharmacokinetics of the different compounds and Robin Braithwaite (Regional Laboratory for Toxicology, Birmingham) described the development and introduction of new more potent BDZ hypnotics with a rapid onset of action, fast rate of elimination and minimal residual effects. Simple differences in the plasma drug concentration-time curve do not fully explain differences in the duration of clinical action and the rate of passage to and from the CSF and brain, together with interaction with BDZreceptor sites, are important factors. The pharmacokinetic properties of some BDZs are more likely to create dependence problems whereas others lend themselves to the management of BDZ withdrawal.
Cognitive impairment with the BDZswas considered by Ian Hindmarch (Department of Psychology, University of Leeds) who suggested that the effects of a tranquillizer might be likened to being 'wrapped in emotional cotton wool'. However, not all compounds are the same, as illustrated by a trial of clobazam compared with lorazepam; the anxiolytic effects were the same but short-term memory was impaired by the latter but not by the former. In another study comparing clobazam with clorazepate, there was a return of anxiety after stopping the clorazepate but relief of anxiety was maintained after stopping clobazam. In a further study of clobazam against bromazepam, the latter was ineffective in relieving anxiety.
On cognitive driving tests clobazam showed no adverse effects whereas lorazepam caused considerable 
